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EMG, mechanical sensitivity, and distribution of experimental groin pain 
ABSTRACT  1 
Objectives: To investigate the effects of experimental adductor pain on the pain referral pattern, 2 
mechanical sensitivity and muscle activity during common clinical tests. 3 
 4 
Design: Repeated-measures design 5 
 6 
Methods: In two separate sessions, 15 healthy males received a hypertonic (painful) and isotonic 7 
(control) saline injection to either the adductor longus (AL) tendon to produce experimental groin 8 
pain or into the rectus femoris (RF) tendon as a painful control. Pain intensity was recorded on a 9 
visual analogue scale (VAS) with pain distribution indicated on body maps. Pressure pain thresholds 10 
(PPT) were assessed bilaterally in the groin area. Electromyography (EMG) of relevant muscles was 11 
recorded during six provocation tests. PPT and EMG assessment were measured before, during and 12 
after experimental pain. 13 
 14 
Results: Hypertonic saline induced higher VAS scores than isotonic saline (p<0.001), and a local pain 15 
distribution in 80% of participants. A proximal pain referral to the lower abdominal region in 33% 16 
(AL) and 7% (RF) of participants. Experimental pain (AL and RF) did not significantly alter PPT 17 
values or the EMG amplitude in groin or trunk muscles during provocation tests when forces were 18 
matched with baseline.  19 
 20 
Conclusions: This study demonstrates that AL tendon pain was distributed locally in the majority of 21 
participants but may refer to the lower abdomen. Experimental adductor pain did not significantly 22 
alter the mechanical sensitivity or muscle activity patterns.  23 
 24 
Key Words: athlete; EMG; pressure pain sensitivity; adductor longus tendon; rectus femoris tendon  25 
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Introduction 26 
The prevalence of hip and groin pain in athletes is generally high with a career prevalence of 45% 27 
reported in professional Australian football players
1
 and a high incidence in sports such as football
2
 28 
and ice hockey.
3
 Adductor-related groin pain is characterised as pain on resisted adduction and pain 29 
on palpation of the adductor longus muscle.
4
 In contrast, abdominal symptoms present with pain on 30 
resisted trunk flexion and pain on palpation of the rectus abdominis distal enthesis.
5
 Yet 31 
characteristics of groin pain per se are poorly understood with few reports of pain referral patterns and 32 
clinical symptomatology. Pain referral patterns are typically semi- (referring distally) or bi-directional 33 
(referring both distally and proximally) with referred pain distributions extending to neighbouring 34 
vertebral segments that are supplying the painful muscle or tendon.
6
 Clinically, pain in both the 35 
adductor and abdominal area is associated with longer recovery times compared to a single site.
7
 The 36 
role of pain referral patterns has not previously been examined and may present a plausible alternate 37 
hypothesis to co-existing pain locations
5, 8-10
 in this region. That is, abdominal pain may present 38 
clinically as a result of referred pain from the adductor region. If this is true, it challenges using pain 39 
location alone as diagnostic criteria in either classifying patients into entities or to specific 40 
pathoanatomical tissue diagnoses. 41 
 42 
Electromyographic (EMG) muscle activity has been shown to be significantly reduced in m. adductor 43 
longus, m. pectineus, and m. gracilis, in patients with a history of groin pain during clinical tests when 44 
compared to healthy activity-matched-controls.
11
 Such changes occur soon after the initiating painful 45 
event.
12
 Given the complex relationship between muscle and fascial structures in the groin and 46 
abdominal region, this possible reduction in muscle activity could shift the balance of the forces 47 
between the adductor and abdominal muscles thus influencing performance during diagnostic testing. 48 
If muscle activation patterns change, it may be possible to maintain the same force output despite the 49 
existence of a painful condition as shown in other pain states.
13, 14
 This may have clinical implications 50 
with regards to the interpretation of clinical diagnostic tests due to alterations in muscle activity and 51 
also the transition from acute into long-standing groin pain.
15
   52 
 53 
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Experimental pain caused by injection of hypertonic saline into tendons in healthy participants has 54 
been shown to cause increased trunk muscle activity,
16, 17
 large pain referral patterns,
16, 18
 regional 55 
hyperalgesia,
16, 18, 19
 and facilitated response to clinical orthopaedic tests for the hips and pelvic girdle. 56 
16, 18, 19
 Therefore, a hypertonic saline model may provide insights into the effect of pain in the groin 57 
region on the muscle activity, mechanical sensitivity, and referral patterns.  58 
 59 
While many studies have focused on the diagnosis of groin pain in athletes, little is understood about 60 
the effect of pain itself on the muscle activation during the diagnostic tests, pain referral patterns, and 61 
mechanical sensitivity, all of which are recommended diagnostic criteria.
4
 This study aimed to 62 
examine three hypotheses surrounding experimental pain at the proximal insertion of the adductor 63 
longus: 1. The pain experienced can radiate superior to the pubic crest. 2. The pain experienced causes 64 
alteration of EMG muscle activity patterns. 3. The pain experienced produces local deep tissue 65 
hyperalgesia. 66 
Methods 67 
Fifteen healthy male participants were included for this study (mean ± SD; age, 26.9 ± 3.4 years; 68 
height, 183.9 ± 5.4 cm; weight, 81.5 ± 7.1 kg). Inclusion criteria were 1) no current or previous hip, 69 
groin, or lumbar region injuries; 2) no signs of neurological disorders or rheumatologic diseases 70 
which could affect the outcome of the experimental procedure; 3) no reported medication use either 71 
on enrolment or on a regular basis; 4) currently participating in regular exercise or sport of total 72 
duration of greater than or equal to 2.5 hours a week. Exclusion criteria were current injury, any 73 
history of pain or injury in the hip, groin, lower abdominal or lumbar regions, a history of lower limb 74 
injury in the previous 2 years, usage of cannabis, opioids or other drugs, current use of pain 75 
medication, previous neurologic, musculoskeletal or mental illnesses, or lack of ability to cooperate. 76 
Participants were given a detailed verbal and written explanation of the experimental procedure. All 77 
participants provided written informed consent. The study was approved by the Danish Regional 78 
Ethics Committee (N-20130036) and conducted in accordance with the Helsinki Declaration.  79 
 80 
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The experiment had a randomized, single-blinded, balanced-crossover, repeated-measures design 81 
conducted in two sessions within one week. Randomisation was achieved through the selection of one 82 
of 16 identical envelopes by an experimenter (blinded to the injector and experimenters) containing 83 
one of all 16 possible order combinations of injection site, side, and injection site. Blinding was 84 
achieved through unlabelled, identical pre-prepared syringes prior to the experimenters entering the 85 
room. The participants were not advised of the order of injections at any stage throughout the 86 
procedure.
20
 Experimental groin pain and a painful control condition outside the groin area were 87 
evaluated. Clinical provocation tests with recordings of the muscle activity and assessment of the 88 
pressure pain sensitivity were administered at baseline, during and after (post-pain) experimental pain 89 
with participant lying supine on a plinth. Prior to baseline testing, all participants were familiarised 90 
with the experimental procedure and confirmed to be pain-free prior to commencing the study. The 91 
post-pain state was defined as five minutes after the cessation of experimental pain. 92 
 93 
The participants participated in two sessions and received one hypertonic and one isotonic saline 94 
injection each session, one in each side of the same site (AL or RF) during each session. The alternate 95 
site was injected in the following session.  The order of the saline type (hypertonic or isotonic) and 96 
site (AL or RF) and side (left or right) was randomised in a balanced way. Groin pain was induced by 97 
injecting sterile hypertonic saline (1 ml, 5.8%) into the adductor longus (AL) tendon with isotonic 98 
saline (1 ml, 0.9%) injected as a non-painful control into the same anatomical site on the contralateral 99 
side within the same session. As a positive (painful) control injection outside the groin area, the 100 
proximal tendon of the long head of the rectus femoris (RF) muscle was injected in a separate session. 101 
The same volume of hypertonic or isotonic saline was injected into the control site as designated by 102 
the randomisation. Participants and injector were blinded to saline type administered. All injections 103 
were given by an orthopaedic surgeon (MI). After a standard disinfection protocol, the injections were 104 
given over the duration of approximately 10 seconds using a 2-ml plastic syringe with a disposable 105 
needle (27G). Pre-defined anatomical landmarks for injection sites for AL and RF tendons were 106 
utilised. The location, depth and alignment of all injection sites were confirmed by real time 107 
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ultrasound (US) imaging (Acuson 128XP10, NativeTM). The AL tendon was identified using a 108 
method previously described.
18
 Both the AL and RF injections positions followed a previously 109 
published protocol (Supplement 1).
20
  110 
 111 
The pain intensity produced by hypertonic saline injections was assessed on a 10 cm electronic visual 112 
analogue scale (VAS) which could be adjusted by using an external handheld slider. The VAS was 113 
anchored with ‘no pain’ and ‘maximum pain’, 0 cm and 10 cm, respectively. A continuous recording 114 
(sample frequency of 20 Hz) of the VAS signal was made after each injection until all pain had 115 
subsided. For analysis, the area under VAS-time curve (VAS area) and VAS-peak were extracted.  116 
   117 
The quality of pain was assessed once the pain had subsided. Participants were allowed to answer 118 
using either the Danish
21
 or English
22
 version of the McGill Pain Questionnaire based upon their 119 
language preference. The Danish results were converted to the English equivalent for analysis. 120 
Participants were asked to mark their pain distribution by filling in a standard body chart. Body areas 121 
were divided into groin regions by using the “Groin Triangle”.
23
 The groin triangle is defined as the 122 
triangle created by the three landmarks: the anterior superior iliac spine (ASIS), pubic tubercle and the 123 
median point between the ASIS and the superior pole of the patella in the anterior coronal plane (‘3G 124 
point’).
24
 Local pain was defined as pain experienced only at the injection site and related “Groin 125 
Triangle” segment while referred pain was defined as any pain felt outside the segment containing the 126 
injection site. The body regions were analysed by registering the frequency of pain experienced in the 127 
region for all four injections.  128 
 129 
Pressure pain thresholds (PPTs) were assessed at regional and distant sites using a handheld pressure 130 
algometer (Somedic, Sweden) with a 1 cm
2 
probe and using a 30 kPa/s ramp. The four bilateral 131 
assessment sites were the AL tendon injection site, the RF tendon injection site, the anterior surface of 132 
the superior pubic rami (PB), and the tibialis anterior (TA) muscle, measured as the proximal site 1/3 133 
the distance from the lateral joint line of the knee to the inferior aspect of the lateral malleolus. Each 134 
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measurement was recorded three times at baseline with two measurements recorded during pain and 135 
post-pain to ensure all testing could be completed within the short-lasting window of saline-induced 136 
pain. The average of the measurements was used for statistical analysis. PPT measurement was ceased 137 
at 1200 kPa to avoid sensitisation after repeated assessments.  138 
 139 
A battery of six pain provocation tests (Supplement 2) was employed with all tests performed by a 140 
single clinically-trained experimenter (MD). All participants were confirmed to be pain-free on all 141 
tests prior commencing the study. The tests administered were as previously published:
20
 1) Bilateral 142 
adduction (squeeze) test with hips at 0° resisted at the ankles
25
 2) A bilateral squeeze test
11
 with hips 143 
flexed at 45° 3) A bilateral squeeze test
11
 with hips flexed to 90°4) Resisted abdominal crunch
25
 5) 144 
Resisted oblique crunch, one side at a time.
25
 The force of contraction was measured using a hand-145 
held dynamometer (MicroFET2, Hoggan Health Industries, USA) at baseline, during-pain and post-146 
pain. The reliability of the 0° adduction test is high (ICC = 0.97, minimal detectable change (%) = 147 
6.6).
26
 Verbal encouragement by the assessor was given to ensure force output remained constant for 148 
each repetition (within 10% of baseline measures). 149 
 150 
The skin at each assessment site was shaved, abraded and cleaned with alcohol in accordance with the 151 
SENIAM guidelines.
27
 Disposable electrodes (Ambu®, Neuroline 720, Denmark) were mounted 152 
bilaterally with an inter-electrode distance of 20 mm in a bipolar configuration at the m. tensor fascia 153 
latae (TFL), the m. adductor longus (AL), m. rectus abdominis (RA), and m. external obliques (EO).
11, 154 
28
 A ground electrode was placed on the right wrist. The EMG signal from the AL muscle was used as 155 
reference to determine the time window for the amplitude analysis (from onset to offset)
29
 where the 156 
root-mean-square (RMS) value was extracted for all muscles during all six tests for the middle epoch 157 
defined as middle third of the period between onset and offset (see Supplement 1 for extended 158 
methodology). The RMS value represents the muscle activity of the muscle. The onsets and offsets 159 
were automatically detected based on the AL muscle EMG data as previously described in detail by 160 
Santello et al.
29
 All onset/offset detections were confirmed by visual inspection at each time point. No 161 
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manual correction of the data was required. Onsets and offsets were not analysed as the research 162 
question investigated related to maximal muscle activity pre-, during and post-experimental pain 163 
conditions rather than changes in the order of activation as a result of pain. Filtered EMG data was 164 
utilised for analysis however filter and normalised data to baseline measures is reported in the 165 
supplements for the ease of interpretation clinically. 166 
 167 
All data was assessed for normality using the Kolmogorov–Smirnov test. Means and standard 168 
deviations (SD) are presented for parametric data. All statistical analyses were performed using Stata 169 
13 IC unless indicated (StataCorp, USA). An a priori estimate of group size indicated 15 participants 170 
were required (estimated 20% difference in effect parameters; α=5%; β=20%; coefficient of 171 
variance=25%). The VAS area was analysed with an analysis of variance (ANOVA) with muscle (AL 172 
and RF) and injection (hypertonic and isotonic) as independent factors. To assess the relationship of 173 
PPTs and the injection site, side and injection type, a linear mixed-effect model (restricted maximum 174 
likelihood [REML] regression) was fitted with PPT site (AL, pubic bone, RF, and tibialis anterior), 175 
injection type (hypertonic and isotonic), side (ipsi- or contralateral) and injection site (RF and AL) 176 
and time (baseline, during or post) and their interactions as fixed-effects. For analysis, filtered EMG 177 
data was utilised to assess the relationship between mean RMS-EMG of each clinical test and the 178 
effects of injection type (isotonic and hypertonic), time point (baseline, during, post-pain), each 179 
muscle (AL, TFL, EO, RA), injection site (AL and RF) and side (ipsilateral and contralateral) and 180 
their interactions with a random effect for participant in a General Linear Mixed Model using the R 181 
package lme4 (R Core Team, 2016).
30
 This approach can handle missing data which created an 182 
unbalanced design.
31
 Means were analysed post-hoc to explain significant effects. Bonferroni 183 
correction was applied where multiple post-hoc analyses were undertaken. Significance was set at 184 
p<0.05 for all statistical tests. 185 
 186 
Results 187 
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The VAS area after hypertonic saline injected into the AL (13112 ± 11147 mm·s) and RF (12110 ± 188 
8829 mm·s) tendons were higher compared with isotonic saline (AL: 206 ± 405 mm·s; RF: 815 ± 189 
2037 mm·s; ANOVA:  F(2,53)=20.05, p<0.001). The VAS-peaks reported for each test condition 190 
were AL isotonic (2 ± 4mm), AL hypertonic (22 ± 12 mm), RF isotonic (4 ± 7 mm), and RF 191 
hypertonic (22 ± 12 mm).The three most common words to describe the sensation after the AL tendon 192 
hypertonic injections were “annoying” (33% of participants), “tugging” (27%) and “pressing” (27%) 193 
whereas the three most common descriptions after the RF tendon hypertonic injections “tight” (47%), 194 
“pressing” (33%), “annoying” (27%) for RF tendon.  195 
  196 
Hypertonic saline-induced pain in the AL tendon primarily demonstrated a local pattern of pain where 197 
it was mainly perceived within and medial to the “Groin Triangle” but also in the lower abdominal 198 
region (Figure 1, Table 1). Injections of hypertonic saline into the RF tendon primarily caused pain 199 
experienced within the triangle and the anterior and lateral thigh indicating a larger pain referral 200 
pattern. During isotonic saline injections into the RF tendon, 11 participants drew the pain on the 201 
anterior thigh. Pain in the contralateral side to the injection was also reported in one participant in 202 
three areas (Figure 1) after the hypertonic injection into the RF tendon. No participants reported pain 203 
on the contralateral side with an absence of pain in the ipsilateral injection side. Therefore, these 204 
reports should be considered as bilateral pain distributions.  205 
 206 
PPT values did not significantly change across time periods under any conditions. Significant fixed 207 
effects were observed for the RF (REML: Coeff=362.5, 95%CI 265.8-564.2, p<0.001) and TA sites 208 
(REML: Coeff=469.8, 95%CI 374.8-561.8, p<0.001) indicating that the TA and RF sites were 209 
generally higher than the adductor and pubic sites. However, no significant fixed effects or 210 
interactions were observed with the inclusion of time (p=0.27-0.99). As time was not a significant 211 
fixed effect, this can be interpreted as the PPT values were not significantly influenced by 212 
experimental pain conditions. The distributions of PPT values across the experimental conditions and 213 
time points are presented in Figure 2. 214 
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 215 
The magnitude of the muscle activity did not change significantly across time periods under any 216 
conditions when compared to baseline conditions. Normalised RMS-EMG for the “during” and “post” 217 
conditions are presented in Supplementary Tables 1-4. A five-way interaction between clinical test, 218 
injection type, muscle, injection site and side was observed (F(15,7771)=8.68, p<0.001) however time 219 
was not a significant fixed effect in the model or any interactions. As time was not a significant fixed 220 
effect it can be interpreted as the muscle activation patterns of the four muscles varied across the 221 
clinical tests, injection type and site, and side when compared to each other yet were not significantly 222 
uninfluenced by the experimental pain. Therefore, no post-hoc analyses were performed. 223 
  224 
Discussion 225 
This is the first study to report the muscle activation pattern involved in commonly used clinical tests 226 
for groin pain and mechanical sensitivity of the lower limb in an experimental pain model. This study 227 
aimed to examine three hypotheses surrounding experimental pain at the proximal insertion of the 228 
adductor longus. The results of this study support the hypothesis that experimental pain in the 229 
proximal adductor longus can proximally refer to the lower abdomen and may explain why pain can 230 
be experienced in both locations clinically. This study fails to provide evidence that experimental pain 231 
in the AL alters the muscle activity and produces local or widespread deep tissue hyperalgesia. These 232 
findings have implications for clinical assessment particularly related to diagnostic or classification 233 
criteria which rely on pain referral patterns as they can be influenced by region structures.  234 
 235 
The AL tendon produced a local pain distribution contained mainly medial to and within the “Groin 236 
Triangle”. Moreover, in 33% of participants the tendon of adductor longus was capable of provoking 237 
proximal referral into the lower abdominal region. This has clinical relevance as it is commonly 238 
reported in the literature that multiple pathologies or clinical entities exist in athletes with groin pain.
5
 239 
Experimentally-induced AL tendon pain is capable of producing false positive test results with 240 
abdominal manoeuvres.
20
 Therefore, comprehensive clinical assessment is required to rule out 241 
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involvement of AL tendon when pain in the lower abdomen is present particularly when coexisting 242 
with pain in the upper inner thigh. The results of experimental pain models
20
 indicate that 45° and 90° 243 
adduction tests have the best negative likelihood ratio, suggesting their utility to rule out adductor 244 
longus as a potential source of nociception. The positive control condition (experimental RF tendon 245 
pain) produced a greater distribution of pain covering the regions within, lateral to and superior to the 246 
groin triangle although no pain was reported medial to the triangle. Bilateral leg pain distribution was 247 
produced in one participant under the RF tendon hypertonic and isotonic saline conditions. This 248 
represents an unusual pain referral pattern that is not typically observed clinically and may be related 249 
to individual characteristics of the participant. 250 
 251 
In the present study, pain induced in adductor and thigh regions was unable to alter the mechanical 252 
sensitivity. Primary mechanical hyperalgesia of the adductor longus tendon has been reported in 253 
Australian football players currently experiencing groin pain.
1
 This indicates the hypertonic saline 254 
tendon pain model may not replicate the clinical pain presentations of groin region. Proximal 255 
(secondary) hyperalgesia has been hypothesised to be explained by amplification of central pain 256 
mechanisms.
32
 No change was observed at the pubic bone or distally on either sides which concurs 257 
with clinical pain studies of the groin region.
1
 The diagnostic criteria for adductor-related groin pain 258 
are pain on resisted adduction tests with tenderness (mechanical sensitivity) on palpation.
4
 In acute 259 
groin injuries, palpation (mechanical sensitivity) has the greatest diagnostic capacity to predict MRI 260 
findings.
33
 In the present study, no changes were observed at the site of the injection or on the pubic 261 
bone PTTs under the AL or RF ipsilateral hypertonic saline-induced pain indicating secondary 262 
mechanical hyperalgesia is less of a concern for this site. Therefore, hyperalgesia of the pubic bone 263 
may represent local mechanical hyperalgesia rather than regional/widespread pain and as such may be 264 
implicated as a nociceptive driver. Clinically, mechanical sensitivity (tenderness on palpation) at the 265 
pubic enthesis may represent local nociception rather than a consequence of adductor tendon pain (as 266 
in the case of secondary hyperalgesia). Confirmation in the clinical setting is warranted however. 267 
 268 
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The magnitude of muscle activity in the region during the painful condition was not statistically 269 
significantly different from the baseline condition. This is hypothesised to be due to the study design 270 
in which force was maintained equal to baseline measures. This indicates that irrespective of pain in 271 
the region, the motor cortex may allow for the task to be completed with equal force production. The 272 
0° adduction test has been suggested to be diagnostically superior to identify experimentally-induced, 273 
adductor-related pain.
20
 However, the results of this paper indicate that changes in muscle activation 274 
less likely to be associated with the diagnostic capabilities reported. Again, this hypothesis should be 275 
tested in clinical populations.  276 
 277 
This study allowed the evaluation of the outcome measures under controlled conditions. This removes 278 
the complications of multiple pathologies detected on clinical assessment
5
 and imaging
8
 in athletes 279 
with groin pain. Nonetheless, pain generated from experimental models differs from clinical pain
18
 280 
and replication of the results in clinical populations is warranted as previously indicated. In the 281 
analysis of PPT and EMG data, a unified linear mixed model was chosen given it ability to account 282 
for the characteristics of the data and to reduce the Type I error associated with multiple sub-grouping 283 
analyses. The lack of positive findings observed may be potentially explained by lower power 284 
however this is offset by the degrees of freedom created by every participant undertaking each 285 
component of the study. Significant variability in the data was observed in the PPT and the level of 286 
pain (VAS) measures across participants. This variability reduced the ability to obtain significant 287 
effects; an increase in sample size is unlikely to alter the results and are likely to represent the 288 
individual nature of the response to pain.  Post-hoc power analyses are therefore not indicated.
34
   289 
 290 
Conclusion 291 
This study has shown that pain arising from the adductor longus tendon is locally distributed in the 292 
majority (80%) but capable of producing pain superior to the pubic crest in 33% of participants. PPTs 293 
were not altered by experimental pain induced by hypertonic saline. An alteration of the magnitude of 294 
EMG activity of the adductor longus, tensor fascia latae, rectus abdominis and external obliques was 295 
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not detected under experimental pain conditions when force was matched to baseline measures. 296 
Therefore, diagnostic criteria based on pain distribution alone may be influenced by pain itself in the 297 
region and may not represent tissue pathology or multiple clinical entities of groin pain. 298 
 299 
 300 
  301 
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Practical Implications 302 
 The adductor longus tendon has a local pattern of pain distribution however can refer 303 
proximally to the lower abdominal region. 304 
 Diagnostic criteria based on pain distribution are potentially influenced by pain itself in the 305 
region and may not represent tissue pathology. 306 
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TABLES 
 
Table 1 Frequency of pain relative to the “Groin Triangle” following injections of hypertonic and isotonic saline into the adductor longus and rectus femoris 
tendons.   
 
 
 Adductor Longus Tendon Rectus Femoris Tendon 
Isotonic saline Hypertonic saline Isotonic saline Hypertonic saline 
Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral 
“Groin Triangle”            
Within the triangle 3 (20) 0 12 (80 %) 0 4 (27%) 1 (7%) 
15 
(100%) 
2 (13%) 
Lateral to the triangle 0 0 1 (7 %) 0 0 0 2 (13%) 0 
Medial to the triangle 7 (47) 0 12 (80%) 0 0 0 0 0 
Superior to the triangle 0   0 5 (33 %)  0  0  0 1 (7%)  0 
Other areas 
        
Greater Trochanter 0 0 0 0 0 0 0 2 (13%) 
Anterior Thigh 0 0 1 (7 %) 0 2 (13%) 0 5 (33%) 2 (13%) 
Lateral Thigh 0 0 0 0 0 0 4 (27%) 1 (7%) 
Knee 0 0 0 0 0 0 0 1 (7%) 
Lower Leg 0 0 0 0 0 0 1 (7%) 2 (13%) 
Foot 0 0   0 0  0 0   0 0  
 
Contralateral/Ipsilateral relative to the side of injection; frequencies reported as number of responses (percentage) 
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FIGURE LEGENDS 
  
 
Figure 1 Pain distributions of the adductor longus are indicated on the body chart’s right side.  
 
Figure 2 Distribution of the pressure pain thresholds at baseline, during pain and post-pain across 
injection types and sites represented as a box-plot. 
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ABSTRACT  1 
Objectives: To investigate the effects of experimental adductor pain on the pain referral pattern, 2 
mechanical sensitivity and muscle activity during common clinical tests. 3 
 4 
Design: Repeated-measures design 5 
 6 
Methods: In two separate sessions, 15 healthy males received a hypertonic (painful) and isotonic 7 
(control) saline injection to either the adductor longus (AL) tendon to produce experimental groin 8 
pain or into the rectus femoris (RF) tendon as a painful control. Pain intensity was recorded on a 9 
visual analogue scale (VAS) with pain distribution indicated on body maps. Pressure pain thresholds 10 
(PPT) were assessed bilaterally in the groin area. Electromyography (EMG) of relevant muscles was 11 
recorded during six provocation tests. PPT and EMG assessment were measured before, during and 12 
after experimental pain. 13 
 14 
Results: Hypertonic saline induced higher VAS scores than isotonic saline (p<0.001), and a local pain 15 
distribution in 80% of participants. A proximal pain referral to the lower abdominal region in 33% 16 
(AL) and 7% (RF) of participants. Experimental pain (AL and RF) did not significantly alter PPT 17 
values or the EMG amplitude in groin or trunk muscles during provocation tests when forces were 18 
matched with baseline.  19 
 20 
Conclusions: This study demonstrates that AL tendon pain was distributed locally in the majority of 21 
participants but may refer to the lower abdomen. Experimental adductor pain did not significantly 22 
alter the mechanical sensitivity or muscle activity patterns.  23 
 24 
Key Words: athlete; EMG; pressure pain sensitivity; adductor longus tendon; rectus femoris tendon  25 
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Introduction 26 
The prevalence of hip and groin pain in athletes is generally high with a career prevalence of 45% 27 
reported in professional Australian football players
1
 and a high incidence in sports such as football
2
 28 
and ice hockey.
3
 Adductor-related groin pain is characterised as pain on resisted adduction and pain 29 
on palpation of the adductor longus muscle.
4
 In contrast, abdominal symptoms present with pain on 30 
resisted trunk flexion and pain on palpation of the rectus abdominis distal enthesis.
5
 Yet 31 
characteristics of groin pain per se are poorly understood with few reports of pain referral patterns and 32 
clinical symptomatology. Pain referral patterns are typically semi- (referring distally) or bi-directional 33 
(referring both distally and proximally) with referred pain distributions extending to neighbouring 34 
vertebral segments that are supplying the painful muscle or tendon.
6
 Clinically, pain in both the 35 
adductor and abdominal area is associated with longer recovery times compared to a single site.
7
 The 36 
role of pain referral patterns has not previously been examined and may present a plausible alternate 37 
hypothesis to co-existing pain locations
5, 8-10
 in this region. That is, abdominal pain may present 38 
clinically as a result of referred pain from the adductor region. If this is true, it challenges using pain 39 
location alone as diagnostic criteria in either classifying patients into entities or to specific 40 
pathoanatomical tissue diagnoses. 41 
 42 
Electromyographic (EMG) muscle activity has been shown to be significantly reduced in m. adductor 43 
longus, m. pectineus, and m. gracilis, in patients with a history of groin pain during clinical tests when 44 
compared to healthy activity-matched-controls.
11
 Such changes occur soon after the initiating painful 45 
event.
12
 Given the complex relationship between muscle and fascial structures in the groin and 46 
abdominal region, this possible reduction in muscle activity could shift the balance of the forces 47 
between the adductor and abdominal muscles thus influencing performance during diagnostic testing. 48 
If muscle activation patterns change, it may be possible to maintain the same force output despite the 49 
existence of a painful condition as shown in other pain states.
13, 14
 This may have clinical implications 50 
with regards to the interpretation of clinical diagnostic tests due to alterations in muscle activity and 51 
also the transition from acute into long-standing groin pain.
15
   52 
 53 
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Experimental pain caused by injection of hypertonic saline into tendons in healthy participants has 54 
been shown to cause increased trunk muscle activity,
16, 17
 large pain referral patterns,
16, 18
 regional 55 
hyperalgesia,
16, 18, 19
 and facilitated response to clinical orthopaedic tests for the hips and pelvic girdle. 56 
16, 18, 19
 Therefore, a hypertonic saline model may provide insights into the effect of pain in the groin 57 
region on the muscle activity, mechanical sensitivity, and referral patterns.  58 
 59 
While many studies have focused on the diagnosis of groin pain in athletes, little is understood about 60 
the effect of pain itself on the muscle activation during the diagnostic tests, pain referral patterns, and 61 
mechanical sensitivity, all of which are recommended diagnostic criteria.
4
 This study aimed to 62 
examine three hypotheses surrounding experimental pain at the proximal insertion of the adductor 63 
longus: 1. The pain experienced can radiate superior to the pubic crest. 2. The pain experienced causes 64 
alteration of EMG muscle activity patterns. 3. The pain experienced produces local deep tissue 65 
hyperalgesia. 66 
Methods 67 
Fifteen healthy male participants were included for this study (mean ± SD; age, 26.9 ± 3.4 years; 68 
height, 183.9 ± 5.4 cm; weight, 81.5 ± 7.1 kg). Inclusion criteria were 1) no current or previous hip, 69 
groin, or lumbar region injuries; 2) no signs of neurological disorders or rheumatologic diseases 70 
which could affect the outcome of the experimental procedure; 3) no reported medication use either 71 
on enrolment or on a regular basis; 4) currently participating in regular exercise or sport of total 72 
duration of greater than or equal to 2.5 hours a week. Exclusion criteria were current injury, any 73 
history of pain or injury in the hip, groin, lower abdominal or lumbar regions, a history of lower limb 74 
injury in the previous 2 years, usage of cannabis, opioids or other drugs, current use of pain 75 
medication, previous neurologic, musculoskeletal or mental illnesses, or lack of ability to cooperate. 76 
Participants were given a detailed verbal and written explanation of the experimental procedure. All 77 
participants provided written informed consent. The study was approved by the Danish Regional 78 
Ethics Committee (N-20130036) and conducted in accordance with the Helsinki Declaration.  79 
 80 
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The experiment had a randomized, single-blinded, balanced-crossover, repeated-measures design 81 
conducted in two sessions within one week. Randomisation was achieved through the selection of one 82 
of 16 identical envelopes by an experimenter (blinded to the injector and experimenters) containing 83 
one of all 16 possible order combinations of injection site, side, and injection site. Blinding was 84 
achieved through unlabelled, identical pre-prepared syringes prior to the experimenters entering the 85 
room. The participants were not advised of the order of injections at any stage throughout the 86 
procedure.
20
 Experimental groin pain and a painful control condition outside the groin area were 87 
evaluated. Clinical provocation tests with recordings of the muscle activity and assessment of the 88 
pressure pain sensitivity were administered at baseline, during and after (post-pain) experimental pain 89 
with participant lying supine on a plinth. Prior to baseline testing, all participants were familiarised 90 
with the experimental procedure and confirmed to be pain-free prior to commencing the study. The 91 
post-pain state was defined as five minutes after the cessation of experimental pain. 92 
 93 
The participants participated in two sessions and received one hypertonic and one isotonic saline 94 
injection each session, one in each side of the same site (AL or RF) during each session. The alternate 95 
site was injected in the following session.  The order of the saline type (hypertonic or isotonic) and 96 
site (AL or RF) and side (left or right) was randomised in a balanced way. Groin pain was induced by 97 
injecting sterile hypertonic saline (1 ml, 5.8%) into the adductor longus (AL) tendon with isotonic 98 
saline (1 ml, 0.9%) injected as a non-painful control into the same anatomical site on the contralateral 99 
side within the same session. As a positive (painful) control injection outside the groin area, the 100 
proximal tendon of the long head of the rectus femoris (RF) muscle was injected in a separate session. 101 
The same volume of hypertonic or isotonic saline was injected into the control site as designated by 102 
the randomisation. Participants and injector were blinded to saline type administered. All injections 103 
were given by an orthopaedic surgeon (MI). After a standard disinfection protocol, the injections were 104 
given over the duration of approximately 10 seconds using a 2-ml plastic syringe with a disposable 105 
needle (27G). Pre-defined anatomical landmarks for injection sites for AL and RF tendons were 106 
utilised. The location, depth and alignment of all injection sites were confirmed by real time 107 
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ultrasound (US) imaging (Acuson 128XP10, NativeTM). The AL tendon was identified using a 108 
method previously described.
18
 Both the AL and RF injections positions followed a previously 109 
published protocol (Supplement 1).
20
  110 
 111 
The pain intensity produced by hypertonic saline injections was assessed on a 10 cm electronic visual 112 
analogue scale (VAS) which could be adjusted by using an external handheld slider. The VAS was 113 
anchored with ‘no pain’ and ‘maximum pain’, 0 cm and 10 cm, respectively. A continuous recording 114 
(sample frequency of 20 Hz) of the VAS signal was made after each injection until all pain had 115 
subsided. For analysis, the area under VAS-time curve (VAS area) and VAS-peak were extracted.  116 
   117 
The quality of pain was assessed once the pain had subsided. Participants were allowed to answer 118 
using either the Danish
21
 or English
22
 version of the McGill Pain Questionnaire based upon their 119 
language preference. The Danish results were converted to the English equivalent for analysis. 120 
Participants were asked to mark their pain distribution by filling in a standard body chart. Body areas 121 
were divided into groin regions by using the “Groin Triangle”.
23
 The groin triangle is defined as the 122 
triangle created by the three landmarks: the anterior superior iliac spine (ASIS), pubic tubercle and the 123 
median point between the ASIS and the superior pole of the patella in the anterior coronal plane (‘3G 124 
point’).
24
 Local pain was defined as pain experienced only at the injection site and related “Groin 125 
Triangle” segment while referred pain was defined as any pain felt outside the segment containing the 126 
injection site. The body regions were analysed by registering the frequency of pain experienced in the 127 
region for all four injections.  128 
 129 
Pressure pain thresholds (PPTs) were assessed at regional and distant sites using a handheld pressure 130 
algometer (Somedic, Sweden) with a 1 cm
2 
probe and using a 30 kPa/s ramp. The four bilateral 131 
assessment sites were the AL tendon injection site, the RF tendon injection site, the anterior surface of 132 
the superior pubic rami (PB), and the tibialis anterior (TA) muscle, measured as the proximal site 1/3 133 
the distance from the lateral joint line of the knee to the inferior aspect of the lateral malleolus. Each 134 
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measurement was recorded three times at baseline with two measurements recorded during pain and 135 
post-pain to ensure all testing could be completed within the short-lasting window of saline-induced 136 
pain. The average of the measurements was used for statistical analysis. PPT measurement was ceased 137 
at 1200 kPa to avoid sensitisation after repeated assessments.  138 
 139 
A battery of six pain provocation tests (Supplement 2) was employed with all tests performed by a 140 
single clinically-trained experimenter (MD). All participants were confirmed to be pain-free on all 141 
tests prior commencing the study. The tests administered were as previously published:
20
 1) Bilateral 142 
adduction (squeeze) test with hips at 0° resisted at the ankles
25
 2) A bilateral squeeze test
11
 with hips 143 
flexed at 45° 3) A bilateral squeeze test
11
 with hips flexed to 90°4) Resisted abdominal crunch
25
 5) 144 
Resisted oblique crunch, one side at a time.
25
 The force of contraction was measured using a hand-145 
held dynamometer (MicroFET2, Hoggan Health Industries, USA) at baseline, during-pain and post-146 
pain. The reliability of the 0° adduction test is high (ICC = 0.97, minimal detectable change (%) = 147 
6.6).
26
 Verbal encouragement by the assessor was given to ensure force output remained constant for 148 
each repetition (within 10% of baseline measures). 149 
 150 
The skin at each assessment site was shaved, abraded and cleaned with alcohol in accordance with the 151 
SENIAM guidelines.
27
 Disposable electrodes (Ambu®, Neuroline 720, Denmark) were mounted 152 
bilaterally with an inter-electrode distance of 20 mm in a bipolar configuration at the m. tensor fascia 153 
latae (TFL), the m. adductor longus (AL), m. rectus abdominis (RA), and m. external obliques (EO).
11, 154 
28
 A ground electrode was placed on the right wrist. The EMG signal from the AL muscle was used as 155 
reference to determine the time window for the amplitude analysis (from onset to offset)
29
 where the 156 
root-mean-square (RMS) value was extracted for all muscles during all six tests for the middle epoch 157 
defined as middle third of the period between onset and offset (see Supplement 1 for extended 158 
methodology). The RMS value represents the muscle activity of the muscle. The onsets and offsets 159 
were automatically detected based on the AL muscle EMG data as previously described in detail by 160 
Santello et al.
29
 All onset/offset detections were confirmed by visual inspection at each time point. No 161 
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manual correction of the data was required. Onsets and offsets were not analysed as the research 162 
question investigated related to maximal muscle activity pre-, during and post-experimental pain 163 
conditions rather than changes in the order of activation as a result of pain. Filtered EMG data was 164 
utilised for analysis however filter and normalised data to baseline measures is reported in the 165 
supplements for the ease of interpretation clinically. 166 
 167 
All data was assessed for normality using the Kolmogorov–Smirnov test. Means and standard 168 
deviations (SD) are presented for parametric data. All statistical analyses were performed using Stata 169 
13 IC unless indicated (StataCorp, USA). An a priori estimate of group size indicated 15 participants 170 
were required (estimated 20% difference in effect parameters; α=5%; β=20%; coefficient of 171 
variance=25%). The VAS area was analysed with an analysis of variance (ANOVA) with muscle (AL 172 
and RF) and injection (hypertonic and isotonic) as independent factors. To assess the relationship of 173 
PPTs and the injection site, side and injection type, a linear mixed-effect model (restricted maximum 174 
likelihood [REML] regression) was fitted with PPT site (AL, pubic bone, RF, and tibialis anterior), 175 
injection type (hypertonic and isotonic), side (ipsi- or contralateral) and injection site (RF and AL) 176 
and time (baseline, during or post) and their interactions as fixed-effects. For analysis, filtered EMG 177 
data was utilised to assess the relationship between mean RMS-EMG of each clinical test and the 178 
effects of injection type (isotonic and hypertonic), time point (baseline, during, post-pain), each 179 
muscle (AL, TFL, EO, RA), injection site (AL and RF) and side (ipsilateral and contralateral) and 180 
their interactions with a random effect for participant in a General Linear Mixed Model using the R 181 
package lme4 (R Core Team, 2016).
30
 This approach can handle missing data which created an 182 
unbalanced design.
31
 Means were analysed post-hoc to explain significant effects. Bonferroni 183 
correction was applied where multiple post-hoc analyses were undertaken. Significance was set at 184 
p<0.05 for all statistical tests. 185 
 186 
Results 187 
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The VAS area after hypertonic saline injected into the AL (13112 ± 11147 mm·s) and RF (12110 ± 188 
8829 mm·s) tendons were higher compared with isotonic saline (AL: 206 ± 405 mm·s; RF: 815 ± 189 
2037 mm·s; ANOVA:  F(2,53)=20.05, p<0.001). The VAS-peaks reported for each test condition 190 
were AL isotonic (2 ± 4mm), AL hypertonic (22 ± 12 mm), RF isotonic (4 ± 7 mm), and RF 191 
hypertonic (22 ± 12 mm).The three most common words to describe the sensation after the AL tendon 192 
hypertonic injections were “annoying” (33% of participants), “tugging” (27%) and “pressing” (27%) 193 
whereas the three most common descriptions after the RF tendon hypertonic injections “tight” (47%), 194 
“pressing” (33%), “annoying” (27%) for RF tendon.  195 
  196 
Hypertonic saline-induced pain in the AL tendon primarily demonstrated a local pattern of pain where 197 
it was mainly perceived within and medial to the “Groin Triangle” but also in the lower abdominal 198 
region (Figure 1, Table 1). Injections of hypertonic saline into the RF tendon primarily caused pain 199 
experienced within the triangle and the anterior and lateral thigh indicating a larger pain referral 200 
pattern. During isotonic saline injections into the RF tendon, 11 participants drew the pain on the 201 
anterior thigh. Pain in the contralateral side to the injection was also reported in one participant in 202 
three areas (Supplementary 3) after the hypertonic injection into the RF tendon. No participants 203 
reported pain on the contralateral side with an absence of pain in the ipsilateral injection side. 204 
Therefore, these reports should be considered as bilateral pain distributions.  205 
 206 
PPT values did not significantly change across time periods under any conditions. Significant fixed 207 
effects were observed for the RF (REML: Coeff=362.5, 95%CI 265.8-564.2, p<0.001) and TA sites 208 
(REML: Coeff=469.8, 95%CI 374.8-561.8, p<0.001) indicating that the TA and RF sites were 209 
generally higher than the adductor and pubic sites. However, no significant fixed effects or 210 
interactions were observed with the inclusion of time (p=0.27-0.99). As time was not a significant 211 
fixed effect, this can be interpreted as the PPT values were not significantly influenced by 212 
experimental pain conditions. The distributions of PPT values across the experimental conditions and 213 
time points are presented in Figure 2. 214 
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 215 
The magnitude of the muscle activity did not change significantly across time periods under any 216 
conditions when compared to baseline conditions. Normalised RMS-EMG for the “during” and “post” 217 
conditions are presented in Supplementary Tables 1-4. A five-way interaction between clinical test, 218 
injection type, muscle, injection site and side was observed (F(15,7771)=8.68, p<0.001) however time 219 
was not a significant fixed effect in the model or any interactions. As time was not a significant fixed 220 
effect it can be interpreted as the muscle activation patterns of the four muscles varied across the 221 
clinical tests, injection type and site, and side when compared to each other yet were not significantly 222 
uninfluenced by the experimental pain. Therefore, no post-hoc analyses were performed. 223 
  224 
Discussion 225 
This is the first study to report the muscle activation pattern involved in commonly used clinical tests 226 
for groin pain and mechanical sensitivity of the lower limb in an experimental pain model. This study 227 
aimed to examine three hypotheses surrounding experimental pain at the proximal insertion of the 228 
adductor longus. The results of this study support the hypothesis that experimental pain in the 229 
proximal adductor longus can proximally refer to the lower abdomen and may explain why pain can 230 
be experienced in both locations clinically. This study fails to provide evidence that experimental pain 231 
in the AL alters the muscle activity and produces local or widespread deep tissue hyperalgesia. These 232 
findings have implications for clinical assessment particularly related to diagnostic or classification 233 
criteria which rely on pain referral patterns as they can be influenced by region structures.  234 
 235 
The AL tendon produced a local pain distribution contained mainly medial to and within the “Groin 236 
Triangle”. Moreover, in 33% of participants the tendon of adductor longus was capable of provoking 237 
proximal referral into the lower abdominal region. This has clinical relevance as it is commonly 238 
reported in the literature that multiple pathologies or clinical entities exist in athletes with groin pain.
5
 239 
Experimentally-induced AL tendon pain is capable of producing false positive test results with 240 
abdominal manoeuvres.
20
 Therefore, comprehensive clinical assessment is required to rule out 241 
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involvement of AL tendon when pain in the lower abdomen is present particularly when coexisting 242 
with pain in the upper inner thigh. The results of experimental pain models
20
 indicate that 45° and 90° 243 
adduction tests have the best negative likelihood ratio, suggesting their utility to rule out adductor 244 
longus as a potential source of nociception. The positive control condition (experimental RF tendon 245 
pain) produced a greater distribution of pain covering the regions within, lateral to and superior to the 246 
groin triangle although no pain was reported medial to the triangle. Bilateral leg pain distribution was 247 
produced in one participant under the RF tendon hypertonic and isotonic saline conditions. This 248 
represents an unusual pain referral pattern that is not typically observed clinically and may be related 249 
to individual characteristics of the participant. 250 
 251 
In the present study, pain induced in adductor and thigh regions was unable to alter the mechanical 252 
sensitivity. Primary mechanical hyperalgesia of the adductor longus tendon has been reported in 253 
Australian football players currently experiencing groin pain.
1
 This indicates the hypertonic saline 254 
tendon pain model may not replicate the clinical pain presentations of groin region. Proximal 255 
(secondary) hyperalgesia has been hypothesised to be explained by amplification of central pain 256 
mechanisms.
32
 No change was observed at the pubic bone or distally on either sides which concurs 257 
with clinical pain studies of the groin region.
1
 The diagnostic criteria for adductor-related groin pain 258 
are pain on resisted adduction tests with tenderness (mechanical sensitivity) on palpation.
4
 In acute 259 
groin injuries, palpation (mechanical sensitivity) has the greatest diagnostic capacity to predict MRI 260 
findings.
33
 In the present study, no changes were observed at the site of the injection or on the pubic 261 
bone PTTs under the AL or RF ipsilateral hypertonic saline-induced pain indicating secondary 262 
mechanical hyperalgesia is less of a concern for this site. Therefore, hyperalgesia of the pubic bone 263 
may represent local mechanical hyperalgesia rather than regional/widespread pain and as such may be 264 
implicated as a nociceptive driver. Clinically, mechanical sensitivity (tenderness on palpation) at the 265 
pubic enthesis may represent local nociception rather than a consequence of adductor tendon pain (as 266 
in the case of secondary hyperalgesia). Confirmation in the clinical setting is warranted however. 267 
 268 
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The magnitude of muscle activity in the region during the painful condition was not statistically 269 
significantly different from the baseline condition. This is hypothesised to be due to the study design 270 
in which force was maintained equal to baseline measures. This indicates that irrespective of pain in 271 
the region, the motor cortex may allow for the task to be completed with equal force production. The 272 
0° adduction test has been suggested to be diagnostically superior to identify experimentally-induced, 273 
adductor-related pain.
20
 However, the results of this paper indicate that changes in muscle activation 274 
less likely to be associated with the diagnostic capabilities reported. Again, this hypothesis should be 275 
tested in clinical populations.  276 
 277 
This study allowed the evaluation of the outcome measures under controlled conditions. This removes 278 
the complications of multiple pathologies detected on clinical assessment
5
 and imaging
8
 in athletes 279 
with groin pain. Nonetheless, pain generated from experimental models differs from clinical pain
18
 280 
and replication of the results in clinical populations is warranted as previously indicated. In the 281 
analysis of PPT and EMG data, a unified linear mixed model was chosen given it ability to account 282 
for the characteristics of the data and to reduce the Type I error associated with multiple sub-grouping 283 
analyses. The lack of positive findings observed may be potentially explained by lower power 284 
however this is offset by the degrees of freedom created by every participant undertaking each 285 
component of the study. Significant variability in the data was observed in the PPT and the level of 286 
pain (VAS) measures across participants. This variability reduced the ability to obtain significant 287 
effects; an increase in sample size is unlikely to alter the results and are likely to represent the 288 
individual nature of the response to pain.  Post-hoc power analyses are therefore not indicated.
34
   289 
 290 
Conclusion 291 
This study has shown that pain arising from the adductor longus tendon is locally distributed in the 292 
majority (80%) but capable of producing pain superior to the pubic crest in 33% of participants. PPTs 293 
were not altered by experimental pain induced by hypertonic saline. An alteration of the magnitude of 294 
EMG activity of the adductor longus, tensor fascia latae, rectus abdominis and external obliques was 295 
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not detected under experimental pain conditions when force was matched to baseline measures. 296 
Therefore, diagnostic criteria based on pain distribution alone may be influenced by pain itself in the 297 
region and may not represent tissue pathology or multiple clinical entities of groin pain. 298 
 299 
 300 
  301 
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Practical Implications 302 
 The adductor longus tendon has a local pattern of pain distribution however can refer 303 
proximally to the lower abdominal region. 304 
 Diagnostic criteria based on pain distribution are potentially influenced by pain itself in the 305 
region and may not represent tissue pathology. 306 
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TABLES 
 
Table 1 Frequency of pain relative to the “Groin Triangle” following injections of hypertonic and isotonic saline into the adductor longus and rectus femoris 
tendons.   
 
 
 Adductor Longus Tendon Rectus Femoris Tendon 
Isotonic saline Hypertonic saline Isotonic saline Hypertonic saline 
Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral 
“Groin Triangle”            
Within the triangle 3 (20) 0 12 (80 %) 0 4 (27%) 1 (7%) 
15 
(100%) 
2 (13%) 
Lateral to the triangle 0 0 1 (7 %) 0 0 0 2 (13%) 0 
Medial to the triangle 7 (47) 0 12 (80%) 0 0 0 0 0 
Superior to the triangle 0   0 5 (33 %)  0  0  0 1 (7%)  0 
Other areas 
        
Greater Trochanter 0 0 0 0 0 0 0 2 (13%) 
Anterior Thigh 0 0 1 (7 %) 0 2 (13%) 0 5 (33%) 2 (13%) 
Lateral Thigh 0 0 0 0 0 0 4 (27%) 1 (7%) 
Knee 0 0 0 0 0 0 0 1 (7%) 
Lower Leg 0 0 0 0 0 0 1 (7%) 2 (13%) 
Foot 0 0   0 0  0 0   0 0  
 
Contralateral/Ipsilateral relative to the side of injection; frequencies reported as number of responses (percentage) 
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FIGURE LEGENDS 
  
 
Figure 1 Pain distributions of the adductor longus are indicated on the body chart’s right side.  
 
Figure 2 Distribution of the pressure pain thresholds at baseline, during pain and post-pain across 
injection types and sites represented as a box-plot. 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Supplement 1 – Extended methodology 
 
Injection position  
 
 
The AL tendon was identified using a method previously described.
13
 The participant lay supine with 
the leg to be injected supported in a slightly abducted, flexed position (figure four position) with the 
heel resting on the knee on the contralateral side. The injection site was along the midline of the 
tendon, 1 cm from the pubic bone. The skin was marked and AL tendon position was confirmed by 
resisting hip adduction under ultrasound imaging.  
 
The RF tendon was found by manual palpation below its attachment to the anterior inferior iliac spine 
and was followed distally towards the musculotendinous junction. The injection site was defined as 
the centre of the tendon of the long head of the rectus femoris muscle. The location and depth of the 
injection was confirmed by the performance of hip flexion against resistance while under ultrasound 
observation. The injection site was marked after confirmation.  
 
Electromyographic placement, sampling and data extraction 
 
 
The skin at each assessment site was shaved, abraded and cleaned with alcohol in accordance 
with the SENIAM guidelines.
20
 Disposable electrodes (Ambu®, Neuroline 720, Denmark) were 
mounted bilaterally with an inter-electrode distance of 20 mm in a bipolar configuration at the m. 
tensor fascia latae (TFL), the m. adductor longus (AL), m. rectus abdominis (RA), and m. external 
obliques (EO).
6,21
 A ground electrode was placed on the right wrist. All electrodes were secured by 
tape (Micropore™ Surgical Tape, 3M™, USA). The electromyographic (EMG) signals were sampled 
at 2048 Hz with a gain of 2000 using a 128-channel surface EMG amplifier (WS1 OT Bioelettronica, 
Italy) and converted to digital form by a 12-bit analogue-to-digital converter (LISiN-OT 
Bioelettronica, Torino, Italy; -3 dB bandwidth 10-500 Hz). The digitized EMG signals were band-
pass filtered (4th order, zero-phase-lag Butterworth, 25 to 450 Hz). The EMG signal from the AL 
muscle was used as reference to determine the time window for the amplitude analysis (from onset to 
offset)
22
 where the root-mean-square (RMS) value was extracted for all muscles for the middle epoch 
Supplementary Material
defined as middle third of the period between onset and offset. The onsets and offsets were 
automatically detected based on the AL muscle EMG data as previously described in detail by 
Santello et al.
22
 In short, the accumulated integrated EMG (iEMG) was normalized to 1 in both 
amplitude and time and subtracted by a reference line with slope equal to 1. The time point where this 
difference was larger was defined as the muscle activity onset. Similar approach was used for the 
offset activity. All onset/offset detections were confirmed by visual inspection at each time point 
(baseline, during pain, post-pain). No manual correction of the data was required.  
  
 
Supplement 2 – Clinical tests 
 
 
 
(a) The 0° adduction test: The participant lay with legs straight and the examiner placed the forearm 
between the medial malleoli with the dynamometer fixed to one end, the participant was instructed to 
adduct maximally. (b) The 45° adduction test: The participant lay with the feet flat on the plinth with 
hips flexed to 45° and the knees at 90° of flexion and performed maximal adduction with the 
dynamometer held in place by the examiner between the medial condyles of the knees. (c) The 90° 
adduction test: the participant lay with the hips and knees at 90° of flexion and performed maximal 
adduction with the dynamometer between the medial femoral condyles. (d) The abdominal crunch 
manoeuvre: the participant performed maximal trunk flexion with the hips and knees in the same 
position as the 45° test. The dynamometer was placed on the sternum where the examiner applied 
resistance to the movement. (e) The oblique crunch manoeuvre: the dynamometer was positioned on 
the shoulder contralateral to the examiner who applied resistance while the participant performed an 
abdominal crunch towards the contralateral knee.  
Supplement 3 – Pain distribution for the control injections 
 
  
Supplementary Table 1. Mean normalised RMG-EMG [95%CI] during the clinical tests after experimentally-induced groin (AL hypertonic injections) and 
thigh pain (RF hypertonic injections). The RMS-EMG is normalised to baseline (100%).  
Injection Test position 
Adductor longus Tensor fascia latae Rectus abdominis External oblique 
Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral 
AL 
Hypertonic 
Injection 
0° adduction 
84.6 
[72.4, 96.7] 
90.3 
[75.88,104.65] 
99.1 
[78.3,119.9] 
102.8 
[85.5,120.2] 
111.7 
[88.8,134.6] 
121.8 
[94.5,149.0] 
116.2 
[90.9,141.4] 
126.2 
[96.6,155.9] 
45° adduction 
92.0 
[80.3,103.8] 
92.3 
[81.1,102.6] 
97.1 
[65.3,128.8] 
95.6 
[70.1,121.1] 
116.3 
[97.1,135.5] 
109.85 
[81.9,137.8] 
118.9 
[95.8,142.0] 
121.0 
[103.3,138.7] 
90° adduction 
104.6 
[92.5,116.7] 
116.7 
[92.8,140.7] 
108.3 
[92.9,123.8] 
126.5 
[93.4,159.7] 
119.3 
[106.9, 131.7] 
118.2 
[106.0, 130.3] 
113.4 
[83.5,143.3] 
125.3 
[95.0,155.6] 
Resisted abdominal 
crunch 
106.4 
[92.8,120.0] 
108.7 
[91.7,125.7] 
161.3 
[104.7,217.8] 
115.6 
[99.8,131.3] 
116.1 
[101.1,131.1] 
102.9 
[93.2,112.6] 
98.0 
[77.6,118.4] 
98.4 
[82.7,114.1] 
Ipsilateral Resisted 
oblique crunch 
95.6 
[81.3,109.8] 
98.8 
[88.9,108.7] 
105.3 
[73.7,137.0] 
103.1 
[93.9,112.4] 
115.9 
[85.8,146.0] 
107.4 
[95.7,119.2] 
99.9 
[82.5,117.3] 
102.8 
[84.3,121.4] 
 
Contralateral Resisted 
oblique crunch 
102.2 
[92.0,112.5] 
111.2 
[81.8,140.6] 
121.5 
[82.9,160.2] 
107.8 
[87.0,128.7] 
116.3 
[83.7,148.8] 
93.7 
[78.0,109.4] 
96.1 
[84.3,107.8] 
99.9 
[86.6,113.2] 
RF 
Hypertonic 
Injection 
0° adduction 
105.8 
[92.5,119.0] 
107.7 
[95.6,119.7] 
112.8 
[94.3,131.3] 
107.9 
[94.6,121.2] 
191.3 
[31.4,351.2] 
152.8 
[71.1,234.5] 
123.9 
[104.3, 143.4] 
120.6 
[101.4, 139.8] 
45° adduction 
94.4 
[86.4,102.4] 
96.4 
[87.9,105.0] 
84.1 
[65.0,103.3] 
100.6 
[77.9,123.3] 
111.1 
[81.8,140.4] 
110.9 
[85.2,136.6] 
104.6 
[81.5,127.8] 
105.0 
[83.0,127.1] 
90° adduction 
106.8 
[91.3,122.3] 
108.9 
[95.8,122.1] 
125.3 
[102.7, 147.9] 
111.7 
[92.8,130.7] 
108.7 
[92.8,124.7] 
111.1 
[92.5,129.7] 
109.6 
[95.8,123.4] 
104.8 
[91.0,118.6] 
Resisted abdominal 
crunch 
113.3 
[103.1, 123.5] 
111.3 
[93.2,129.5] 
114.3 
[90.0,144.7] 
108.7 
[82.1,135.3] 
105.3 
[95.3,115.3] 
108.0 
[98.4,117.6] 
102.6 
[75.5,129.7] 
101.5 
[81.2, 121.8] 
Ipsilateral Resisted 
oblique crunch 
105.3 
[92.7,117.9] 
105.9 
[85.6,126.3] 
140.0 
[72.3,207.7] 
103.4 
[88.9,117.8] 
111.0 
[98.6,123.5] 
113.5 
[100.3, 126.7] 
116.0 
[98.5,133.5] 
116.3 
[100.4,132.2] 
 
Contralateral Resisted 
oblique crunch 
91.2 
[76.2,106.3] 
97.4 
[67.9,127.0] 
89.2 
[67.8,110.6] 
83.4 
[65.7,101.1] 
102.4 
[87.5,117.2] 
106.2 
[87.9,124.6] 
96.7 
[79.0,114.4] 
99.9 
[74.5,125.3] 
Supplementary Table 2. Mean normalised RMG-EMG [95%CI] during the clinical tests after control injections into the groin (AL isotonic injections) and 
thigh (RF isotonic injections). The RMS-EMG is normalised to baseline (100%). 
Injection Test position 
Adductor longus Tensor fascia latae Rectus abdominis External oblique 
Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral 
AL 
Isotonic 
Injection 
0° adduction 
96.5 
[87.1,106.0] 
95.3 
[86.3,104.3] 
137.6 
[52.5,222.6] 
113.5 
[78.5,148.4] 
122.3 
[90.9,153.6] 
142.9 
[83.6,202.3] 
108.8 
[89.4,128.2] 
106.0 
[87.1,124.9] 
45° adduction 
108.6 
[96.8,120.4] 
109.4 
[95.3,123.6] 
111.3 
[92.2,130.4] 
129.1 
[97.1,161.1] 
128.7 
[89.4,167.9] 
280.5 
[-77.9,638.9] 
113.4 
[95.0,131.8] 
128.5 
[99.9,157.1] 
90° adduction 
103.6 
 [90.0,117.3] 
101.4 
[88.1,114.6] 
97.2 
[77.7,116.6] 
99.3 
[84.2,114.5] 
120.8 
[56.7,185.0] 
162.7 
[120.0,313.3] 
109.5 
[93.5,125.4] 
111.4 
[91.2,131.6] 
Resisted abdominal 
crunch 
116.9 
[98.2,137.6] 
100.5 
[85.8,115.2] 
100.0 
[83.5,116.4] 
97.9 
[83.0,112.8] 
105.2 
[95.9,114.5] 
106.3 
[80.1,132.5] 
91.3 
[82.2,100.3] 
96.8 
[81.0,112.6] 
Ipsilateral Resisted 
oblique crunch 
106.7 
[88.8,124.6] 
105.7 
[94.8,116.6] 
108.9 
[90.4,127.4] 
119.2 
[88.2,150.1] 
101.6 
[86.3,116.9] 
112.8 
[86.5,139.0] 
93.3 
[82.1,104.5] 
90.7 
[78.8,102.6] 
 
Contralateral Resisted 
oblique crunch 
106.9 
[94.8,118.9] 
110.5 
[90.6,130.5] 
101.7 
[87.7,115.7] 
117.1 
[94.7,139.5] 
114.8 
[91.1,138.5] 
139.6 
[88.9,190.4] 
103.1 
[91.8,114.3] 
100.0 
[86.4,113.6] 
RF 
Isotonic 
Injection 
0° adduction 
105.0 
[91.8,118.2] 
102.4 
[90.7,114.2] 
132.9 
[64.2,201.5] 
140.7 
[60.0,221.4] 
115.9 
[91.1,140.8] 
110.2 
[85.7,134.6] 
109.3 
[85.0,133.7] 
108.8 
[84.8,132.8] 
45° adduction 
102.1 
[92.1,112.2] 
103.6 
[94.4,112.8] 
104.8 
[84.3,125.4] 
132.1 
[76.6,187.5] 
98.4 
[87.2,109.7] 
102.7 
[92.5,113.0] 
110.9 
[87.3,134.4] 
110.1 
[85.0,135.3] 
90° adduction 
106.7 
[92.7,120.6] 
104.5 
[91.1,117.9] 
133.0 
[81.3,184.6] 
106.1 
[87.6,124.7] 
91.9 
[67.7,116.2] 
93.8 
[65.9,121.6] 
96.2 
[78.4,114.1] 
92.4 
[78.5,106.4] 
Resisted abdominal 
crunch 
102.3 
[92.3,112.3] 
107.3 
[88.3,126.4] 
101.8 
[77.1,126.5] 
111.2 
[95.1,127.4] 
89.1 
[76.9,101.3] 
90.0 
[78.0,101.9] 
93.4 
[81.5,105.4] 
88.8 
[74.0,103.6] 
Ipsilateral Resisted 
oblique crunch 
120.1 
[98.3,141.8] 
124.2 
[93.7,154.7] 
124.0 
[84.2,163.8] 
111.7 
[86.8,136.7] 
109.3 
[82.6,136.0] 
105.8 
[81.6,130.1] 
110.5 
[90.5,130.5] 
110.8 
[86.8,134.9] 
 
Contralateral Resisted 
oblique crunch 
110.5 
[92.8,128.2] 
108.4 
[88.2,128.5] 
105.4 
[92.1,118.7] 
102.0 
[88.2,115.9] 
100.6 
[85.7,115.5] 
99.3 
[84.8,113.9] 
100.7 
[91.3,110.2] 
99.8 
[90.6,108.9] 
  
 
Supplementary Table 3. Mean normalised RMG-EMG [95%CI] during the clinical tests in the post-pain condition after experimentally-induced groin (AL 
hypertonic injections) and thigh pain (RF hypertonic injections) had resolved. The RMS-EMG is normalised to baseline (100%). 
Injection Test position 
Adductor longus 
mean (%), [95% CI] 
Tensor fascia latae 
mean (%), [95% CI] 
Rectus abdominis 
mean (%), [95% CI] 
External oblique 
mean (%), [95% CI] 
Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral 
AL 
Hypertonic 
Injection 
0° adduction 
93.7 
[79.1,108.4] 
96.5 
[86.6,106.5] 
99.1 
[78.3,119.9] 
102.8 
[85.5,120.2] 
115.5 
[78.6,12.5] 
119.8 
[87.0,152.7] 
116.3 
[84.1,148.4] 
115.5 
[87.9,143.1] 
45° adduction 
98.9 
[87.4,110.4] 
98.5 
[88.9,108.2] 
120.9 
[89.4,152.3] 
121.5 
[91.6,151.3] 
116.5 
[94.6,138.4] 
106.2 
[90.7,121.6] 
116.2 
[93.0,139.4] 
117.2 
[88.4,146.0] 
90° adduction 
103.0 
[90.0,116.0] 
106.2 
[93.2,119.3] 
101.3 
[90.7,111.8] 
128.1 
[88.7,167.5] 
110.2 
[92.8,127.6] 
102.9 
[93.2,112.6] 
105.4 
[87.4,123.5] 
118.3 
[97.1,139.5] 
Resisted abdominal 
crunch 
101.7 
[89.3,114.0] 
102.3 
[87.3,117.4] 
138.6 
[105.5,171.7] 
103.0 
[85.2,120.8] 
98.0 
[87.6,108.4] 
106.1 
[96.1,116.1] 
104.8 
[81.3,128.4] 
94.9 
[83.6,106.2] 
Ipsilateral Resisted 
oblique crunch 
117.0 
[87.1,147.0] 
110.1 
[98.3,121.8] 
102.5 
[83.8,121.3] 
108.6 
[82.3,135.0] 
119.8 
[85.6,153.9] 
119.4 
[93.2,145.5] 
103.5 
[82.5,124.5] 
109.4 
[82.0,136.8] 
 
Contralateral Resisted 
oblique crunch 
125.8 
[89.8,161.8] 
108.6 
[99.0,118.2] 
121.5 
[81.2,161.9] 
129.7 
[96.1,163.2] 
105.3 
[88.7,121.9] 
99.1 
[84.2,113.9] 
100.1 
[83.5,116.6] 
100.0 
[86.4,113.6] 
RF 
Hypertonic 
Injection 
0° adduction 
107.3 
[96.5,118.1] 
111.2 
[98.0,124.5] 
110.6 
[94.7,126.5] 
107.9 
[85.7,130.1] 
133.0 
[43.8,222.2] 
108.0 
[64.4,151.7] 
105.1 
[87.3,123.0] 
101.4 
[84.2,118.7] 
45° adduction 
106.1 
[97.2,115.0] 
105.1 
[97.5,112.6] 
96.5 
[75.2,117.9] 
118.6 
[86.5,150.6] 
98.3 
[90.0,106.6] 
100.6 
[91.7,109.5] 
104.1 
[88.7,119.5] 
102.8 
[90.1,115.5] 
90° adduction 
106.3 
[93.0,119.6] 
106.2 
[91.9,120.6] 
128.9 
[100.7,149.1] 
116.8 
[92.9,140.7] 
111.6 
[93.7,129.6] 
116.0 
[95.1,137.0] 
109.0 
[92.7,125.2] 
105.5 
[88.8,122.3] 
Resisted abdominal 
crunch 
103.0 
[90.1,116.0] 
102.1 
[94.4,109.7] 
111.6 
[83.3,140.0] 
115.9 
[95.6,136.2] 
110.3 
[101.0,119.5] 
113.9 
[102.8,125.0] 
108.8 
[83.6,134.0] 
108.2 
[85.5,130.9] 
Ipsilateral Resisted 
oblique crunch 
108.0 
[83.9,132.1] 
100.5 
[80.8,120.3] 
97.0 
[86.3,107.7] 
104.1 
[83.5,124.6] 
111.8 
[88.9,134.8] 
113.3 
[98.4,128.3] 
112.2 
[93.3,131.1] 
111.1 
[96.0,126.2] 
 
Contralateral Resisted 
oblique crunch 
92.1 
[72.5,111.7] 
92.8 
[77.4,108.1] 
91.7 
[73.2,110.2] 
85.6 
[67.7,103.5] 
92.6 
[78.0,107.1] 
95.1 
[79.4,110.8] 
93.7 
[76.5,110.9] 
96.2 
[72.7,119.6] 
 
 
Supplementary Table 4. Mean normalised RMG-EMG [95%CI] during the clinical tests in the post-pain condition after control injections into the groin (AL 
isotonic injections) and thigh (RF isotonic injections). The RMS-EMG is normalised to baseline (100%). 
Injection Test position 
Adductor longus Tensor fascia latae Rectus abdominis External oblique 
Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral 
AL 
Isotonic 
Injection 
0° adduction 
101.8 
[88.5,115.1] 
111.0 
[94.3,127.8] 
113.5 
[80.1,146.9] 
103.8 
[71.2,136.4] 
118.0 
[93.4,142.6] 
118.2 
 [89.3,147.1] 
104.1 
[84.4,123.8] 
117.6 
[91.0,144.1] 
45° adduction 
110.6 
[97.3,123.9] 
109.4 
[94.8,124.0] 
129.9 
[79.0,180.8] 
114.2 
[89.5,138.9] 
125.3 
[75.8,174.8] 
125.6 
[87.4,163.7] 
125.8 
[85.6,166.1] 
117.7 
[98.15,137.2] 
90° adduction 
105.5 
[86.7,124.3] 
103.7 
[92.2,115.1] 
105.1 
[78.5,131.7] 
104.6 
[82.0,127.2] 
89.1 
[70.8,107.4] 
89.1 
[74.5,107.4] 
101.2 
[85.1,105.4] 
104.9 
[86.2,123.7] 
Resisted abdominal 
crunch 
104.8 
[84.6,124.9] 
113.9 
[95.3,132.5] 
95.9 
[75.9,116.0] 
87.4 
[68.6,106.1] 
106.4 
[86.1,126.7] 
110.6 
[95.0,126.1] 
104.3 
[94.0,114.6] 
99.4 
[90.9,108.0] 
Ipsilateral Resisted 
oblique crunch 
100.2 
[83.3,117.2] 
126.3 
[96.6,155.9] 
116.5 
[83.4,149.7] 
113.6 
[79.6,147.7] 
98.8 
[83.6,114.0] 
103.8 
[87.7,119.9] 
92.6 
[76.0,109.3] 
97.1 
[80.9,113.2] 
 
Contralateral Resisted 
oblique crunch 
117.1 
[88.9,145.4] 
97.5 
[78.5,116.5] 
127.7 
[106.0,149.4] 
107.2 
[64.5,149.9] 
129.3 
[89.5,169.1] 
134.0 
[83.4,184.6] 
97.3 
[83.5,111.1] 
116.9 
[82.5,151.3] 
RF 
Isotonic 
Injection 
0° adduction 
107.4 
[93.1,121.8] 
115.1 
[101.4,128.8] 
180.8 
[54.3,307.2] 
118.6 
[85.7,151.6] 
131.2 
[95.1,167.3] 
134.1 
[93.7,174.5] 
145.6 
[104.1,187.2] 
132.3 
[96.5,168.1] 
45° adduction 
101.5 
[91.0,112.1] 
100.2 
[89.6,110.8] 
133.3 
[85.64,180.9] 
150.9 
[92.1,209.7] 
91.0 
[76.0,106.0] 
86.7 
[73.9,99.4] 
91.6 
[78.7,104.5] 
94.4 
[78.9,109.9] 
90° adduction 
100.2 
[89.4,110.9] 
99.6 
[89.4,109.8] 
133.9 
[88.4,179.5] 
163.0 
[87.9,238.2] 
81.7 
[67.8,95.6] 
82.6 
[70.9,94.3] 
89.2 
[75.1,108.9] 
89.2 
[73.8,104.6] 
Resisted abdominal 
crunch 
112.9 
[89.0,136.9] 
103.1 
[87.0,119.1] 
102.1 
[78.8,125.4] 
122.5 
[78.7,166.3] 
102.1 
[80.3,123.9] 
103.4 
[93.3,113.5] 
99.2 
[86.9,111.6] 
106.6 
[95.4,117.8] 
Ipsilateral Resisted 
oblique crunch 
111.1 
[82.1,140.1] 
110.9 
[99.2,122.6] 
99.9 
[77.7,122.1] 
167.3 
[39.3,295.4] 
100.6 
[84.1,117.1] 
117.7 
[95.7,139.7] 
102.2 
[88.3,116.1] 
110.6 
[88.0,133.1] 
 
Contralateral Resisted 
oblique crunch 
101.2 
[83.0,119.4] 
97.5 
[82.0,112.9] 
128.2 
[80.2,176.2] 
97.9 
[83.8,111.7] 
98.8 
[80.9,116.7] 
103.9 
[89.8,118.1] 
96.7 
[83.8,109.6] 
100.5 
[87.5,113.5] 
 
 
